Press Releases

Date Title and Summary
Toggle Summary Seventh CyberKnife System in South Korea Purchased
CyberKnife for Installation at Gyeongsang National University Hospital Will Expand Patient Access SUNNYVALE, Calif ., Aug. 12 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that the Gyeongsang National University Hospital
Toggle Summary Shanghai's First CyberKnife(R) System Installed at Major Academic Oncology Center
Install Marks the Fifth System in China and 121st CyberKnife System Installation SUNNYVALE, Calif, Nov. 27 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Hua Shan Hospital in Shanghai has installed a CyberKnife(R)
Toggle Summary South Florida Radiation Oncology Treats First Cancer Patients Using Its New CyberKnife® M6™ System
Innovative Radiation Therapy Device Enables Cancer Center to Provide Faster, Extremely Precise Radiation Treatments SUNNYVALE, Calif. , April 24, 2018 /PRNewswire/ -- Accuray Incorporated's (NASDAQ: ARAY) CyberKnife ® M6™ System with the InCise™ Multileaf Collimator (MLC) is enabling clinicians at
Toggle Summary St. Louis University Hospital Purchases Second CyberKnife(R) System
Major Academic Center Expands Cancer Treatment Access to Local Community SUNNYVALE, Calif., March 3 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that St. Louis University Hospital has purchased a second CyberKnife(R)
Toggle Summary St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings
Non-Invasive Treatment Alternative will be Centerpiece to Expansion of Radiation Oncology Facility SUNNYVALE, Calif., July 24 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that St.
Toggle Summary Stanford Study on CyberKnife Radiosurgery for Prostate Cancer Demonstrates 100 Percent PSA Response at 33 months
Prior Studies Demonstrate Frequency of Prostate Motion, Supporting Need for the CyberKnife System's Real-Time Tracking to Spare Surrounding Sensitive Structures SUNNYVALE, Calif ., March 31 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery,
Toggle Summary Stanford University Medical Center to Acquire Second Accuray CyberKnife® M6™ System
New System will be Used to Treat Diseases in the Brain and Base of the Skull SUNNYVALE, Calif. , Dec. 4, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Stanford University Medical Center has selected a second CyberKnife ® M6™ System to expand access to precise
Toggle Summary Studies Support Growing Use of the Accuray TomoTherapy® System for Breast Cancer to Improve Tumor Control with Reduced Toxicities
Additional Data Demonstrate Accuray TomoTherapy and CyberKnife® Systems Provide Precise Dose Delivery and Tumor Management SUNNYVALE, Calif. , Sept. 18, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that studies presented at the 56th Annual American Society for Radiation
Toggle Summary Studies Support Use of the Accuray TomoTherapy® System for Advanced Rectal Cancer to Improve Treatment Efficacy and Reduce Side Effects
SUNNYVALE, Calif. , Feb. 5, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that two new studies demonstrate the benefits of the TomoTherapy ® System  in the treatment of advanced rectal cancer. Radiotherapy, with or without chemotherapy, followed by surgery is the
Toggle Summary Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors
CyberKnife System Broadens Range of Lung Cancer Patients Treatable with SBRT   SUNNYVALE, Calif. , Jan. 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today publication of a study demonstrating the benefits of the CyberKnife® Robotic

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.